{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nabilone in Reference Text / Citation (approximate match)
Showing 1 - 3 of 3 results
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
Canbisol is dihydroxyhexahydrodibenzo(b,d)pyran derivative patented by pharmaceutical company Eli Lilly and Co. as antihypertensive agent. At the dosages studied, Canbisol reduced food consumption by rats.
Status:
US Previously Marketed
Source:
CESAMET by BAUSCH
(1985)
Source URL:
First approved in 1985
Source:
CESAMET by BAUSCH
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Nabilone is a synthetic cannabinoid approved under the brand name cesamet for treatment of severe nausea and vomiting associated with cancer chemotherapy. Nabilone is an orally active which, like other cannabinoids, has complex effects on the central nervous system (CNS). It has been suggested that the antiemetic effect of nabilone is caused by interaction with the cannabinoid receptor system, i.e. the CB (1) receptor, which has been discovered in neural tissues.